SCHEMBL9718424

SCHEMBL9718424

CCCCCCCCCCN(CCCCCCCCCC)[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 12/20 0.47
NOD1 Q9Y239 2/20 0.46
PPARG P37231 7/20 0.42
PPARD Q03181 7/20 0.42
PPARA Q07869 7/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
PTPN1 P18031 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
MEN1 O00255 1/20 0.42
ESR1 P03372 1/20 0.42
ALOX15 P16050 1/20 0.42
PDE4A P27815 1/20 0.42
KMT2A Q03164 1/20 0.42
PDE3A Q14432 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15047639 1.00 GPR84 (0.47) GPR84NOD1PPARGPPARDPPARA
SCHEMBL2213923 1.00 GPR84 (0.47) GPR84NOD1PPARGPPARDPPARA
SCHEMBL2283334 1.00 GPR84 (0.47) GPR84NOD1PPARGPPARDPPARA
SCHEMBL2214034 1.00 GPR84 (0.47) GPR84NOD1PPARGPPARDPPARA
SCHEMBL9442148 1.00 GPR84 (0.47) GPR84NOD1PPARGPPARDPPARA
SCHEMBL7567415 1.00 GPR84 (0.47) GPR84NOD1PPARGPPARDPPARA
Carbamic Acid SCHEMBL2289549 0.95 NOD1 (0.46) GPR84NOD1PPARGPPARDPPARA
SCHEMBL19852728 0.93 GPR84 (0.44) GPR84NOD1PPARGPPARDPPARA
SCHEMBL31321524 0.93 GPR84 (0.44) GPR84NOD1PPARGPPARDPPARA
Hydrochloric Acid SCHEMBL3914766 0.91 GPR84 (0.40) GPR84NOD1PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180311316-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 ADOCIA (FR) 2018-11-01 US claimed
US-20170182131-A9 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 ADOCIA (FR) 2017-06-29 US claimed
EP-2741765-B9 INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN ADOCIA (FR) 2016-09-28 EP claimed
EP-2741765-B1 INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN ADOCIA (FR) 2016-03-30 EP claimed
US-20150250858-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 ADOCIA (FR) 2015-09-10 US claimed
US-9089476-B2 Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 ADOCIA (FR) 2015-07-28 US claimed
US-20130065826-A1 Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 ADOCIA (FR) 2013-03-14 US claimed
US-20120309680-A1 Functionalized oligosaccharides ADOCIA (FR) 2012-12-06 US claimed
US-10449256-B2 Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer ADOCIA (FR) 2019-10-22 US disclosed
US-20180311316-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 ADOCIA (FR) 2018-11-01 US disclosed
US-20180169249-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER ADOCIA (FR) 2018-06-21 US disclosed
US-20170182131-A9 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 ADOCIA (FR) 2017-06-29 US disclosed
US-20150314003-A2 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER ADOCIA (FR) 2015-11-05 US disclosed
US-20150250858-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 ADOCIA (FR) 2015-09-10 US disclosed
US-9089476-B2 Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 ADOCIA (FR) 2015-07-28 US disclosed
US-9018190-B2 Functionalized oligosaccharides ADOCIA (FR) 2015-04-28 US disclosed
US-20140249079-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANONIC POLYMER ADOCIA (FR) 2014-09-04 US disclosed
US-20130065826-A1 Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 ADOCIA (FR) 2013-03-14 US disclosed
US-20120309680-A1 Functionalized oligosaccharides ADOCIA (FR) 2012-12-06 US disclosed
US-5139807-A Replacements for fats and oils in foods NABISCO, INC. (US) 1992-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170182131-A9 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 IAPP, IGFBP5, INSR GPR84 3987/4885NOD1 1075/4885PPARG 503/4885
US-20180311316-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 IAPP, IGFBP5, INSR GPR84 3987/4885NOD1 1075/4885PPARG 503/4885
US-20150250858-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 IAPP, IGFBP5, INSR GPR84 3987/4885NOD1 1075/4885PPARG 503/4885
US-20180169249-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER IAPP, IGFBP5, IDE GPR84 2483/4885NOD1 2512/4885PPARG 2561/4885
US-20120309680-A1 Functionalized oligosaccharides OSTC, STT3A, DDOST GPR84 1185/4885NOD1 595/4885PPARG 4647/4885
US-10449256-B2 Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer IAPP, IGFBP5, IDE GPR84 2483/4885NOD1 2512/4885PPARG 2561/4885
US-20150314003-A2 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER IAPP, IGFBP5, IDE GPR84 2483/4885NOD1 2512/4885PPARG 2561/4885
US-20130065826-A1 Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 IAPP, IGFBP5, INSR GPR84 3987/4885NOD1 1075/4885PPARG 503/4885
US-20140249079-A1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANONIC POLYMER IAPP, IGFBP5, IDE GPR84 2704/4885NOD1 2775/4885PPARG 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.